Varlilumab Explained

Varlilumab (INN;[1] development code CDX-1127) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.[2] It is an anti-CD27 antibody and helps activate T-cells.[3]

This drug was developed by Celldex Therapeutics.

It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer. In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours

Notes and References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 . WHO Drug Information . 28 . 2 . 2014 .
  2. http://www.ama-assn.org/resources/doc/usan/x-pub/varlilumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Varlilumab
  3. Web site: Melão A. Varlilumab-Opdivo Combo Stabilizes or Shrinks Tumors in 80% of Solid-cancer Patients, Trial Shows . June 2017 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Varlilumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.